Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

This study explores whether the hormone oxytocin — sometimes called the 'bonding hormone' — can help improve bone density in children with autism spectrum disorder (ASD). Children with ASD often have lower bone density than their peers, which can lead to fractures and long-term health problems. Oxytocin is already being studied for its effects on social behaviour in autism, but this trial specifically examines its impact on bone health. Participants must be children aged 6–18 with a clinical diagnosis of ASD and a body mass index at or above the 5th percentile. A parent or guardian must be available to provide consent. Children with certain genetic syndromes, conditions affecting bone density (like hypogonadism), specific medications that impact bone (like some anti-seizure drugs), seizures in the last 6 months, heart problems, or kidney/liver dysfunction are excluded. Participants will receive oxytocin (or a placebo) and attend regular visits for blood tests and bone density scans. The research matters because bone health is a neglected concern in autism, and if oxytocin — already under investigation for other symptoms — also improves bone density, it could offer a dual benefit for children with ASD.